![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PSMC3 |
Gene summary for PSMC3 |
![]() |
Gene information | Species | Human | Gene symbol | PSMC3 | Gene ID | 5702 |
Gene name | proteasome 26S subunit, ATPase 3 | |
Gene Alias | DCIDP | |
Cytomap | 11p11.2 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A140VK42 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5702 | PSMC3 | GSM4909281 | Human | Breast | IDC | 4.96e-02 | 2.22e-01 | 0.21 |
5702 | PSMC3 | GSM4909288 | Human | Breast | IDC | 2.74e-02 | 1.35e-01 | 0.0988 |
5702 | PSMC3 | GSM4909296 | Human | Breast | IDC | 1.21e-05 | -2.65e-02 | 0.1524 |
5702 | PSMC3 | GSM4909297 | Human | Breast | IDC | 2.51e-09 | -7.98e-02 | 0.1517 |
5702 | PSMC3 | GSM4909311 | Human | Breast | IDC | 2.23e-22 | -2.06e-01 | 0.1534 |
5702 | PSMC3 | GSM4909312 | Human | Breast | IDC | 2.10e-09 | -8.23e-02 | 0.1552 |
5702 | PSMC3 | GSM4909319 | Human | Breast | IDC | 2.77e-27 | -1.52e-01 | 0.1563 |
5702 | PSMC3 | GSM4909320 | Human | Breast | IDC | 3.12e-02 | -1.96e-01 | 0.1575 |
5702 | PSMC3 | GSM4909321 | Human | Breast | IDC | 2.97e-08 | -3.14e-03 | 0.1559 |
5702 | PSMC3 | brca1 | Human | Breast | Precancer | 6.32e-26 | 6.42e-01 | -0.0338 |
5702 | PSMC3 | brca2 | Human | Breast | Precancer | 2.29e-18 | 5.20e-01 | -0.024 |
5702 | PSMC3 | brca3 | Human | Breast | Precancer | 1.56e-03 | 1.62e-01 | -0.0263 |
5702 | PSMC3 | NCCBC14 | Human | Breast | DCIS | 6.14e-05 | -9.03e-02 | 0.2021 |
5702 | PSMC3 | NCCBC2 | Human | Breast | DCIS | 6.02e-04 | -2.43e-01 | 0.1554 |
5702 | PSMC3 | NCCBC5 | Human | Breast | DCIS | 1.08e-11 | 1.35e-01 | 0.2046 |
5702 | PSMC3 | P1 | Human | Breast | IDC | 2.29e-13 | -1.43e-01 | 0.1527 |
5702 | PSMC3 | P2 | Human | Breast | IDC | 1.03e-03 | 2.19e-01 | 0.21 |
5702 | PSMC3 | DCIS2 | Human | Breast | DCIS | 1.44e-50 | 1.29e-01 | 0.0085 |
5702 | PSMC3 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.21e-11 | 2.34e-01 | -0.1808 |
5702 | PSMC3 | HTA11_1938_2000001011 | Human | Colorectum | AD | 5.88e-11 | 3.37e-01 | -0.0811 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005181711 | Endometrium | EEC | modulation of process of other organism involved in symbiotic interaction | 20/2168 | 81/18723 | 7.45e-04 | 7.02e-03 | 20 |
GO:005185112 | Endometrium | EEC | modulation by host of symbiont process | 15/2168 | 60/18723 | 2.88e-03 | 2.03e-02 | 15 |
GO:003582112 | Endometrium | EEC | modulation of process of other organism | 22/2168 | 106/18723 | 4.53e-03 | 2.92e-02 | 22 |
GO:00517027 | Endometrium | EEC | biological process involved in interaction with symbiont | 20/2168 | 94/18723 | 4.94e-03 | 3.11e-02 | 20 |
GO:004217627 | Esophagus | HGIN | regulation of protein catabolic process | 119/2587 | 391/18723 | 8.09e-18 | 2.43e-15 | 119 |
GO:001049826 | Esophagus | HGIN | proteasomal protein catabolic process | 139/2587 | 490/18723 | 1.20e-17 | 3.41e-15 | 139 |
GO:001603227 | Esophagus | HGIN | viral process | 118/2587 | 415/18723 | 3.01e-15 | 6.22e-13 | 118 |
GO:004586227 | Esophagus | HGIN | positive regulation of proteolysis | 107/2587 | 372/18723 | 2.61e-14 | 4.60e-12 | 107 |
GO:004316126 | Esophagus | HGIN | proteasome-mediated ubiquitin-dependent protein catabolic process | 114/2587 | 412/18723 | 7.00e-14 | 1.20e-11 | 114 |
GO:190336227 | Esophagus | HGIN | regulation of cellular protein catabolic process | 81/2587 | 255/18723 | 1.16e-13 | 1.93e-11 | 81 |
GO:000989626 | Esophagus | HGIN | positive regulation of catabolic process | 126/2587 | 492/18723 | 1.46e-12 | 2.09e-10 | 126 |
GO:003133126 | Esophagus | HGIN | positive regulation of cellular catabolic process | 112/2587 | 427/18723 | 5.15e-12 | 6.72e-10 | 112 |
GO:190305027 | Esophagus | HGIN | regulation of proteolysis involved in cellular protein catabolic process | 70/2587 | 221/18723 | 6.21e-12 | 7.76e-10 | 70 |
GO:006113627 | Esophagus | HGIN | regulation of proteasomal protein catabolic process | 60/2587 | 187/18723 | 1.10e-10 | 1.12e-08 | 60 |
GO:004573227 | Esophagus | HGIN | positive regulation of protein catabolic process | 69/2587 | 231/18723 | 1.66e-10 | 1.64e-08 | 69 |
GO:190336427 | Esophagus | HGIN | positive regulation of cellular protein catabolic process | 51/2587 | 155/18723 | 1.01e-09 | 8.15e-08 | 51 |
GO:190180020 | Esophagus | HGIN | positive regulation of proteasomal protein catabolic process | 41/2587 | 114/18723 | 2.25e-09 | 1.67e-07 | 41 |
GO:190305219 | Esophagus | HGIN | positive regulation of proteolysis involved in cellular protein catabolic process | 45/2587 | 133/18723 | 3.55e-09 | 2.53e-07 | 45 |
GO:004440326 | Esophagus | HGIN | biological process involved in symbiotic interaction | 71/2587 | 290/18723 | 7.09e-07 | 3.00e-05 | 71 |
GO:001908016 | Esophagus | HGIN | viral gene expression | 28/2587 | 94/18723 | 4.52e-05 | 1.09e-03 | 28 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0305010 | Breast | Precancer | Proteasome | 25/684 | 46/8465 | 4.35e-16 | 9.81e-15 | 7.52e-15 | 25 |
hsa0501714 | Breast | Precancer | Spinocerebellar ataxia | 29/684 | 143/8465 | 2.79e-06 | 3.83e-05 | 2.94e-05 | 29 |
hsa0516918 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0305013 | Breast | Precancer | Proteasome | 25/684 | 46/8465 | 4.35e-16 | 9.81e-15 | 7.52e-15 | 25 |
hsa0501715 | Breast | Precancer | Spinocerebellar ataxia | 29/684 | 143/8465 | 2.79e-06 | 3.83e-05 | 2.94e-05 | 29 |
hsa0516919 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0501224 | Breast | IDC | Parkinson disease | 107/867 | 266/8465 | 2.57e-39 | 8.36e-37 | 6.26e-37 | 107 |
hsa0502023 | Breast | IDC | Prion disease | 102/867 | 273/8465 | 3.70e-34 | 4.01e-32 | 3.00e-32 | 102 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PSMC3 | SNV | Missense_Mutation | novel | c.427N>C | p.Glu143Gln | p.E143Q | P17980 | protein_coding | tolerated(0.11) | benign(0.157) | TCGA-A2-A4RW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PSMC3 | SNV | Missense_Mutation | c.149N>A | p.Ser50Asn | p.S50N | P17980 | protein_coding | tolerated(1) | benign(0.001) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PSMC3 | SNV | Missense_Mutation | c.874N>A | p.Gly292Ser | p.G292S | P17980 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A1HE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PSMC3 | SNV | Missense_Mutation | c.73N>A | p.Glu25Lys | p.E25K | P17980 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
PSMC3 | SNV | Missense_Mutation | novel | c.532N>C | p.Asp178His | p.D178H | P17980 | protein_coding | deleterious(0.02) | probably_damaging(0.97) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
PSMC3 | SNV | Missense_Mutation | c.73N>A | p.Glu25Lys | p.E25K | P17980 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
PSMC3 | SNV | Missense_Mutation | rs771618920 | c.329A>G | p.Asn110Ser | p.N110S | P17980 | protein_coding | tolerated(0.2) | benign(0) | TCGA-A6-3810-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PSMC3 | SNV | Missense_Mutation | c.380N>T | p.Ser127Phe | p.S127F | P17980 | protein_coding | deleterious(0) | possibly_damaging(0.868) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
PSMC3 | SNV | Missense_Mutation | novel | c.375N>C | p.Lys125Asn | p.K125N | P17980 | protein_coding | deleterious(0.04) | possibly_damaging(0.535) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PSMC3 | SNV | Missense_Mutation | c.1178N>A | p.Gly393Glu | p.G393E | P17980 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5702 | PSMC3 | NA | inhibitor | BORTEZOMIB | BORTEZOMIB | |
5702 | PSMC3 | NA | inhibitor | CARFILZOMIB | CARFILZOMIB | |
5702 | PSMC3 | NA | inhibitor | CHEMBL2103884 | OPROZOMIB | |
5702 | PSMC3 | NA | inhibitor | CHEMBL451887 | CARFILZOMIB | |
5702 | PSMC3 | NA | BORTEZOMIB | BORTEZOMIB | 24524217 | |
5702 | PSMC3 | NA | inhibitor | CHEMBL325041 | BORTEZOMIB | |
5702 | PSMC3 | NA | CARFILZOMIB | CARFILZOMIB | 24524217 | |
5702 | PSMC3 | NA | inhibitor | CHEMBL3545432 | IXAZOMIB CITRATE |
Page: 1 |